Mwyngil Therapeutics to deal with weight problems, however with out GLP-1s

Allison covers what scorching startups are getting as much as, and who’s financing them. She can be co-host of the weekly biotech podcast, “The Readout Loud.” You may attain Allison on Sign at AllisonDeAngelis.01.

A brand new startup is making a daring transfer on this planet of weight problems drug growth: It’s not working with the GLP-1 goal that has taken the world by storm.

Just some years in the past, the time period “GLP-1” would have been a international idea to most People. Now, it’s in every single place — on billboards, TV commercials, and journal articles. Most startups hoping to edge their method into the multibillion-dollar weight reduction market have their very own GLP-1 drug candidate. However not Mwyngil Therapeutics. 

Mwyngil — pronounced “mwin-gull” — is finding out methods to spur weight reduction with out focusing on the GLP-1 receptor. That’s what attracted CEO Luba Greenwood, a biotech veteran, to the corporate. “I used to be not keen on one other ‘me too’ GLP-1, or GLP-1 plus one thing. … That’s not very attention-grabbing science,” she informed STAT, in her first interview in regards to the firm.